12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-28), Cogent Biosciences's 12-1 Month Momentum % is -45.87%.
The industry rank for Cogent Biosciences's 12-1 Month Momentum % or its related term are showing as below:
COGT's 12-1 Month Momentum % is ranked worse than 71.78% of 1481
companies
in the Biotechnology industry
Industry Median: -20.83
vs COGT: -45.87
Competitive Comparison of Cogent Biosciences's 12-1 Month Momentum %
For the Biotechnology subindustry, Cogent Biosciences's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences's 12-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Cogent Biosciences 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Cogent Biosciences's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cogent Biosciences (Cogent Biosciences) Business Description
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COGT has been successfully added to your